Pliant Therapeutics, Inc. (PLRX)

Pliant Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	1.58	9.69	7.57	41.82
Revenue Growth (YoY)	-	-83.69%	27.91%	-81.89%	-26.70%
Gross Profit	-	1.58	9.69	7.57	41.82
Selling, General & Admin	59.06	57.93	39.95	27.56	17.27
Research & Development	169.31	127.8	96.94	77.55	66.19
Operating Expenses	228.37	185.73	136.89	105.11	83.46
Operating Income	-228.37	-184.15	-127.2	-97.54	-41.65
Interest Expense	-3.02	-1.27	-0.79	-	-
Interest & Investment Income	21.09	24.08	4.67	0.27	0.11
Pretax Income	-210.3	-161.34	-123.32	-97.26	-41.53
Net Income	-210.3	-161.34	-123.32	-97.26	-41.53
Net Income to Common	-210.3	-161.34	-123.32	-97.26	-41.53
Shares Outstanding (Basic)	61	59	42	36	21
Shares Outstanding (Diluted)	61	59	42	36	21
Shares Change (YoY)	3.10%	39.75%	17.21%	67.94%	1214.82%
EPS (Basic)	-3.47	-2.75	-2.94	-2.71	-1.95
EPS (Diluted)	-3.47	-2.75	-2.94	-2.71	-1.95
Free Cash Flow	-159.35	-117.28	-96.39	-77.4	-38.8
Free Cash Flow Per Share	-2.63	-2.00	-2.29	-2.16	-1.82
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-11654.75%	-1313.37%	-1288.10%	-99.59%
Profit Margin	-	-10211.14%	-1273.32%	-1284.51%	-99.32%
Free Cash Flow Margin	-	-7422.91%	-995.26%	-1022.13%	-92.79%
EBITDA	-226.24	-182.3	-125.38	-96	-40.34
EBITDA Margin	-	-	-	-	-96.46%
D&A For EBITDA	2.13	1.84	1.82	1.54	1.31
EBIT	-228.37	-184.15	-127.2	-97.54	-41.65
EBIT Margin	-	-	-	-	-99.59%

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q